LAUSR

https://ejgo.org Epithelial ovarian cancer (EOC) is usually diagnosed as a locally advanced disease (International Federation of Gynecology and Obstetrics 2018 stages III/IV) and is the most lethal gynecological cancer in developed countries [1]. Primary treatment usually consists of debulking surgery followed by adjuvant platinum/taxane therapy [2]. In the 80s and 90s, a marked gain in overall survival (OS) was observed with the introduction of cisplatin and paclitaxel in the treatment of EOC, respectively. Since then, the development and approval of new drugs has not been as impressive as those seen in other malignancies, such as lung, breast cancer and melanoma.